These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28592622)

  • 1. Li-Fraumeni versus Pseudo-Li-Fraumeni Syndrome: Key Insights for Interpreting Next-Generation Sequencing Reports in Patients with Suspected Cancer Predisposition Syndromes.
    Sorscher S; Desnoyers R; Ouyang K; Ramkissoon S
    Oncologist; 2017 Sep; 22(9):1084-1085. PubMed ID: 28592622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome.
    MacFarland SP; Zelley K; Long JM; McKenna D; Mamula P; Domchek SM; Nathanson KL; Brodeur GM; Rustgi AK; Katona BW; Maxwell KN
    Gastroenterology; 2019 Jan; 156(1):273-274. PubMed ID: 30243621
    [No Abstract]   [Full Text] [Related]  

  • 3. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
    Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
    JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next generation sequencing is informing phenotype: a TP53 example.
    O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
    Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of Li-Fraumeni syndrome, a hereditary cancer predisposition disorder.
    Miranda Alcalde B; Villa Alcázar M; Martínez Romera I; López Ibor B
    Arch Argent Pediatr; 2021 Feb; 119(1):e11-e17. PubMed ID: 33458985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic analysis in a patient with nine primary malignant neoplasms: a rare case of Li-Fraumeni syndrome.
    Li X; Kang J; Pan Q; Sikora-Wohlfeld W; Zhao D; Meng C; Bai C; Patwardhan A; Chen R; Ren H; Butte AJ; Ding K
    Oncol Rep; 2016 Mar; 35(3):1519-28. PubMed ID: 26707089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic counseling can influence the course of a suspected familial cancer syndrome patient: from a case of Li-Fraumeni like syndrome with a germline mutation in the TP53 gene.
    Hwang SM; Lee ES; Shin SH; Kong SY
    Korean J Lab Med; 2008 Dec; 28(6):493-7. PubMed ID: 19127115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Li-Fraumeni syndrome: the genetics and treatment considerations for the sarcoma and associated neoplasms.
    Upton B; Chu Q; Li BD
    Surg Oncol Clin N Am; 2009 Jan; 18(1):145-56, ix. PubMed ID: 19056046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
    Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
    Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 Testing for Li-Fraumeni and Li-Fraumeni-like syndromes.
    Gonzalez K; Fong C; Buzin C; Sommer SS; Saldivar JS
    Curr Protoc Hum Genet; 2008 Apr; Chapter 10():Unit 10.10. PubMed ID: 18428420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Li-Fraumeni syndrome--a molecular and clinical review.
    Varley JM; Evans DG; Birch JM
    Br J Cancer; 1997; 76(1):1-14. PubMed ID: 9218725
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic and functional analysis of a Li Fraumeni syndrome family in China.
    Hu H; Liu J; Liao X; Zhang S; Li H; Lu R; Li X; Lin W; Liu M; Xia Z; Qing G; Li JD
    Sci Rep; 2016 Jan; 6():20221. PubMed ID: 26818906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
    Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
    Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline TP53 mutations and Li-Fraumeni syndrome.
    Varley JM
    Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
    Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
    Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
    Nemunaitis JM; Nemunaitis J
    Future Oncol; 2008 Dec; 4(6):759-68. PubMed ID: 19086841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing.
    Zampiga V; Danesi R; Tedaldi G; Tebaldi M; Cangini I; Pirini F; Pittureri C; Amaducci E; Guidi L; Faedi M; Amadori D; Falcini F; Calistri D
    Int J Biol Markers; 2016 Dec; 31(4):e461-e465. PubMed ID: 27516001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Li-Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations.
    Dermawan JK; Abramson DH; Chiang S; Hensley ML; Tap WD; Movva S; Maki RG; Mandelker D; Antonescu CR
    Clin Cancer Res; 2024 Oct; 30(20):4780-4790. PubMed ID: 39150540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.